TY  - RPRT
TI  - Quantitative cancer-immunity cycle modeling to optimize bevacizumab and atezolizumab combination therapy for advanced renal cell carcinoma
AU  - Lei Du
AU  - Chenghang Li
AU  - Jinzhi Lei
PY  - 2026
UR  - https://arxiv.org/abs/2601.17669
ID  - 2601.17669
ER  -